Fig. 7: Schematic illustration of the molecular mechanism by which LASS2 inhibits the liver cancer progression.

LASS2 exerts its tumor-suppressive effects in a p53-dependent manner, in which LASS2 interacts with MDM2/MDMX and causes dual inhibition to disrupt p53 degradation by MDM2/MDMX.